| Year | Title | Author(s) |
| 2018 |
The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities
Mabs |
Dhagat, U Hercus, TR Broughton, SE Nero, TL Shing, KSCT Barry, EF Thomson, CA Bryson, S Pai, EF McClure, BJ Schrader, JW Lopez, AF Parker, MW |
| 2016 |
Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling
Structure |
Broughton, SE Hercus, TR Nero, TL Dottore, M McClure, BJ Dhagat, U Taing, H Gorman, MA King-Scott, J Lopez, AF Parker, MW |
| 2016 |
CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common beta chain of the IL-3, GM-CSF and IL-5 receptors
Mabs |
Panousis, C Dhagat, U Edwards, KM Rayzman, V Hardy, MP Braley, H Gauvreau, GM Hercus, TR Smith, S Sehmi, R McMillan, L Dottore, M McClure, BJ Fabri, LJ Vairo, G Lopez, AF Parker, MW Nash, AD Wilson, NJ Wilson, MJ Owczarek, CM |
| 2014 |
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.
Cell Rep |
Parker, MW Hercus, TR Hardy, MP Broughton, SE McClure, BJ Dottore, M Huynh, H Braley, H Barry, EF Kan, WL Dhagat, U Scotney, PD Hartman, D Busfield, SJ Owczarek, CM Nash, AD Wilson, NJ Lopez, AF |